Case report · 2021
Conference abstractPublished 2014
MicroRNA in multiple sclerosis: New biomarkers and potential targets for treatment
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Agrowing body of scientific evidence indicates that microRNAs (miRNA) are abnormally expressed in patients with multiple sclerosis (MS). B cells are implicated in the pathogenesis of MS. The role of miRNA in MS is not well understood. It was studied if miRNAs regulate pro-inflammatory capabilities of B cells in MS. B cells and monocytes were separated from untreated patients with MS and age- and gender-matched control healthy subjects (CHS). Expression of 904 miRNAs was tested by microarrays followed by validation with real-time qPCR. Expression of miR-320 was significantly decreased in B cells of patients compared to CHS, p=0.014, but not in monocytes. Protein expression of Matrix metallopeptidase 9 (MMP-9), the protein implicated in disruption of blood-brain barrier and is specifically targeted by miR-320, was significantly increased in B cells of patients. To test whether endogenous miRNA-320 inhibits MMP-9 secretion and TFRC expression, B cells from CHS were transfected with specific miR-320 inhibitor which led to increased MMP-9 expression and secretion. In summary, miR-320 expression is selectively decreased in B cells of patients with MS. This is associated with increased expression of miR- 320-specific target, MMP-9, which promotes blood-brain barrier disruption. The author will discuss promise and obstacles in using microRNAs as biomarkers of disease activity and potential targets for MS treatment.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 7 Sep 2017
A novel biomarker-based tool to monitor multiple sclerosis evolution at clinical and sub-clinical stages: Antibody-proteases as a new generation of translational tools to monitor, to predict and to prevent demyelination
Review article · 2014
The Role of Autonomic Dysregulation from Pathophysiology to Therapeutics of Multiple Sclerosis: A Putative Novel Treatment Target?
Conference abstract · 1 Dec 2016
The story of Glatiramer acetate (Copaxone) in the treatment of multiple sclerosis: The potential for neuroprotection by immunomodulatory treatment
Conference abstract · 1 Dec 2016
The story of glatiramer acetate (Copaxone) in the treatment of multiple sclerosis - The potential for neuroprotection by immunomodulat
More from this journal
The newest in Journal of Neurology & Neurophysiology.
Article · 31 Mar 2025
Neural coding and sensory integration in somatosensory cortex
Conference abstract · 3 Feb 2025
The Most common cause of falls without cause in geriatric patients
Conference abstract · 3 Feb 2025
Neuroimaging by Evaluation Nerverenovate and Neuroplasticity of Acupuncture in Children with Cerebral Palsy
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology & Neurophysiology
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Konstantin E Balashov”
- BylineArticles whose byline prints “Latt Latt Aung”

